Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dextrorphan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 6/20 | 0.98 |
| ▸ | OPRD1 | P41143 | 5/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 8/20 | 0.98 |
| ▸ | GRIN2A | Q12879 | 8/20 | 0.98 |
| ▸ | GRIN2D | O15399 | 7/20 | 0.98 |
| ▸ | GRIN3B | O60391 | 7/20 | 0.98 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.98 |
| ▸ | GRIN2C | Q14957 | 7/20 | 0.98 |
| ▸ | GRIN3A | Q8TCU5 | 7/20 | 0.98 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.98 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.98 |
| ▸ | MRGPRX2 | Q96LB1 | 3/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.98 |
| ▸ | SCN1A | P35498 | 2/20 | 0.98 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.98 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levorphanol SCHEMBL442528 | 1.00 | OPRD1 (1.00) | OPRD1GRIN1GRIN2AGRIN2DGRIN3B | |
| Levorphanol SCHEMBL32667565 | 1.00 | OPRD1 (1.00) | OPRD1GRIN1GRIN2AGRIN2DGRIN3B | |
| Levorphanol SCHEMBL24335 | 0.99 | GRIN1 (1.00) | OPRD1GRIN1GRIN2AGRIN2DGRIN3B | |
| Levorphanol SCHEMBL3495833 | 0.99 | GRIN1 (1.00) | OPRD1GRIN1GRIN2AGRIN2DGRIN3B | |
| Levorphanol SCHEMBL16310821 | 0.99 | GRIN1 (1.00) | OPRD1GRIN1GRIN2AGRIN2DGRIN3B | |
| Levorphanol SCHEMBL12232844 | 0.99 | GRIN1 (1.00) | OPRD1GRIN1GRIN2AGRIN2DGRIN3B | |
| Levorphanol SCHEMBL21095576 | 0.99 | GRIN1 (1.00) | OPRD1GRIN1GRIN2AGRIN2DGRIN3B | |
| Levorphanol SCHEMBL22722062 | 0.99 | GRIN1 (1.00) | OPRD1GRIN1GRIN2AGRIN2DGRIN3B | |
| Dextrorphan SCHEMBL20535964 | 0.99 | GRIN1 (1.00) | OPRD1GRIN1GRIN2AGRIN2DGRIN3B | |
| Levorphanol SCHEMBL22791693 | 0.99 | GRIN1 (1.00) | OPRD1GRIN1GRIN2AGRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-12605333-B2 | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release | TRIS PHARMA, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260098013-A1 | Stereoisomer Conjugates of Dextrorphan | ZEVRA THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250339367-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12403090-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| WO-1999026620-A1 | CHOLINE ESTERS OF FATTY ACIDS AND THEIR USE IN THE TREATMENT OF STROKE | PROTARGA, INC. (US) | 1999-06-03 | — | — | WO | disclosed |
| EP-0909183-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | Neuromedica, Inc. (US) | 1999-04-21 | — | — | EP | disclosed |
| WO-1998050044-A1 | COMPOSITION AND METHOD COMBINING AN ANTIDEPRESSANT WITH AN NMDA RECEPTOR ANTAGONIST, FOR TREATING NEUROPATHIC PAIN | ALGOS PHARMACEUTICAL CORPORATION (US) | 1998-11-12 | — | — | WO | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
| US-5019579-A | Antitussive Agents | PRODOTTI FORMETI S.R.L. (IT) | 1991-05-28 | — | — | US | disclosed |
| EP-0219896-A1 | Pharmaceutical compositions on the basis of dextrorphan for intranasal application | PRODOTTI FORMENTI S.r.l. (IT) | 1987-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605333-B2 | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release | SI, GRPR, FABP2 | OPRM1 735/4885OPRD1 550/4885GRIN1 334/4885 |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | OPRM1 1993/4885OPRD1 2462/4885GRIN1 2190/4885 |
| US-20260098013-A1 | Stereoisomer Conjugates of Dextrorphan | OPRM1, OPRD1, OPRK1 | OPRM1 1/4885OPRD1 2/4885GRIN1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.